A new option for the treatment of refractory epilepsy—Vigabatrin

Vigabatrin (Vigabatrin), a high-profile anti-epileptic drug, is gradually becoming a powerful assistant in the treatment of refractory epilepsy, especially infantile spasms (West syndrome). Infantile spasms, a severe type of epilepsy that may appear in infancy, is characterized by brief muscle twitches and accompanying loss of consciousness. Without timely intervention, it is likely to have long-term effects on the patient's cognition and development. Therefore, finding an efficient and safe therapeutic drug is of vital significance to improving patient prognosis.

Vigabatrin stands out among many anti-epileptic drugs due to its unique mechanism of action. It can effectively increase the concentration of GABA in the brain by inhibiting the activity of γ-aminobutyric acid (GABA) aminotransferase. GABA, as a key inhibitory neurotransmitter, plays a pivotal role in regulating neuronal excitability. Vigabatrin utilizes this mechanism to successfully reduce the over-excitability of neurons, thereby effectively controlling epileptic seizures. Especially for patients who have poor response to traditional anti-epileptic drugs, it has brought significant curative effects.

In addition to infantile spasms, Vigabatrin has also shown considerable strength in the treatment of other refractory epilepsy types such as complex partial epilepsy. These types of epilepsy are often difficult to effectively control with conventional drugs, and the emergence of Vigabatrin undoubtedly provides patients with a new treatment option. Clinical data shows that many patients have significantly reduced the frequency of epileptic seizures and significantly improved their quality of life after receiving Vigabatrin treatment.

Of course, the use of any medication comes with a certain risk of side effects. Vigabatrin is no exception. Patients may encounter adverse reactions such as drowsiness, fatigue, and mood changes during treatment. It is particularly worth noting that long-term use of Vigabatrin may cause visual field defects, and this side effect is often irreversible. Therefore, during the medication process, doctors will closely monitor the patient's response, especially their vision, to ensure the safety and effectiveness of the treatment.